Ubs Asset Management Americas Inc Insmed Inc Transaction History

Ubs Asset Management Americas Inc

$477 Billion
Q2 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Insmed Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 695,961 shares of INSM stock, worth $109 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

695,961

Previous 539,484 29.0%

Holding current value

$109 Million

Previous $41.2 Million 70.18%

% of portfolio

0.01%

Previous 0.01%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$64.81 - $105.9 $10.1 Million - $16.6 Million	156,477 Added 29.0%	695,961 $70 Million
Q1 2025 May 19, 2025	BUY	$65.25 - $83.83 $3.43 Million - $4.41 Million	52,637 Added 10.81%	539,484 $41.2 Million
Q4 2024 Feb 14, 2025	BUY	$66.29 - $76.63 $4.24 Million - $4.9 Million	63,911 Added 15.11%	486,847 $33.6 Million
Q3 2024 Nov 14, 2024	SELL	$62.0 - $79.01 $887,778 - $1.13 Million	-14,319 Reduced 3.27%	422,936 $30.9 Million
Q2 2024 Aug 13, 2024	BUY	$22.0 - $69.71 $665,060 - $2.11 Million	30,230 Added 7.43%	437,255 $29.3 Million
Q1 2024 May 15, 2024	SELL	$25.72 - $29.94 $14,017 - $16,317	-545 Reduced 0.13%	407,025 $11 Million
Q4 2023 Feb 14, 2024	BUY	$23.42 - $31.74 $1.03 Million - $1.39 Million	43,940 Added 12.08%	407,570 $12.6 Million
Q3 2023 Nov 13, 2023	BUY	$19.86 - $26.93 $215,917 - $292,782	10,872 Added 3.08%	363,630 $9.18 Million
Q1 2023 May 15, 2023	SELL	$16.26 - $21.73 $42,519 - $56,823	-2,615 Reduced 0.74%	352,758 $6.01 Million
Q4 2022 Feb 14, 2023	BUY	$16.98 - $23.15 $454,096 - $619,100	26,743 Added 8.14%	355,373 $7.1 Million
Q3 2022 Nov 14, 2022	SELL	$20.88 - $28.21 $2.56 Million - $3.47 Million	-122,837 Reduced 27.21%	328,630 $7.08 Million
Q2 2022 Aug 12, 2022	SELL	$17.07 - $25.71 $127,820 - $192,516	-7,488 Reduced 1.63%	451,467 $8.9 Million
Q1 2022 May 16, 2022	BUY	$20.42 - $28.13 $6.74 Million - $9.28 Million	330,065 Added 256.08%	458,955 $10.8 Million
Q4 2021 Feb 14, 2022	BUY	$25.89 - $33.45 $349,256 - $451,240	13,490 Added 11.69%	128,890 $3.51 Million
Q3 2021 Nov 15, 2021	SELL	$22.46 - $29.47 $170,696 - $223,972	-7,600 Reduced 6.18%	115,400 $3.18 Million
Q2 2021 Aug 16, 2021	BUY	$24.17 - $36.01 $159,425 - $237,521	6,596 Added 5.67%	123,000 $3.5 Million
Q1 2021 May 14, 2021	BUY	$32.28 - $44.3 $80,732 - $110,794	2,501 Added 2.2%	116,404 $3.96 Million
Q4 2020 Mar 01, 2021	BUY	$31.45 - $40.54 $322,897 - $416,224	10,267 Added 9.91%	113,903 $3.79 Million
Q3 2020 Nov 13, 2020	SELL	$26.0 - $34.5 $56,290 - $74,692	-2,165 Reduced 2.05%	103,636 $3.33 Million
Q2 2020 Aug 14, 2020	BUY	$14.11 - $29.42 $79,622 - $166,017	5,643 Added 5.63%	105,801 $2.91 Million
Q1 2020 May 15, 2020	BUY	$13.63 - $33.98 $140,184 - $349,484	10,285 Added 11.44%	100,158 $1.61 Million
Q4 2019 Feb 14, 2020	BUY	$16.12 - $24.98 $25,485 - $39,493	1,581 Added 1.79%	89,873 $2.15 Million
Q3 2019 Nov 14, 2019	BUY	$15.49 - $25.78 $232,830 - $387,499	15,031 Added 20.52%	88,292 $1.56 Million
Q2 2019 Aug 15, 2019	BUY	$23.0 - $32.19 $612,398 - $857,090	26,626 Added 57.09%	73,261 $0
Q1 2019 May 14, 2019	BUY	$13.91 - $31.15 $96,187 - $215,402	6,915 Added 17.41%	46,635 $0
Q4 2018 Feb 13, 2019	SELL	$11.6 - $18.7 $117,194 - $188,926	-10,103 Reduced 20.28%	39,720 $521,000
Q3 2018 Nov 14, 2018	SELL	$18.95 - $28.08 $4,604 - $6,823	-243 Reduced 0.49%	49,823 $0
Q2 2018 Aug 14, 2018	SELL	$20.0 - $29.72 $68,760 - $102,177	-3,438 Reduced 6.43%	50,066 $0
Q1 2018 May 14, 2018	BUY	$21.69 - $32.99 $164,084 - $249,569	7,565 Added 16.47%	53,504 $0
Q4 2017 Feb 09, 2018	BUY	$26.43 - $31.78 $537,691 - $646,532	20,344 Added 79.48%	45,939 $0
Q3 2017 Nov 13, 2017	BUY	$11.61 - $31.21 $297,157 - $798,819	25,595	25,595 $0

Others Institutions Holding INSM

# of Institutions

581

Shares Held

203M

Call Options Held

2.84M

Put Options Held

3.26M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $21.3B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Insmed Inc Transaction History